JP2017522046A - 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 - Google Patents

生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 Download PDF

Info

Publication number
JP2017522046A
JP2017522046A JP2017516650A JP2017516650A JP2017522046A JP 2017522046 A JP2017522046 A JP 2017522046A JP 2017516650 A JP2017516650 A JP 2017516650A JP 2017516650 A JP2017516650 A JP 2017516650A JP 2017522046 A JP2017522046 A JP 2017522046A
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally substituted
aryl
polynucleotide construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017516650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522046A5 (enExample
Inventor
ブラッドショー，コート，ダブリュ．
サカムリ，スクマー
エルテプ，ラクスマン
ラム，ソン
リウ，ディングオ
ミード，ブライアン
イアコノ，ギウセッペ，デッロ
ストック，ジョセフ
リウ，ビン
Original Assignee
ソルスティス バイオロジクス，リミティッド
ソルスティス バイオロジクス，リミティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソルスティス バイオロジクス，リミティッド, ソルスティス バイオロジクス，リミティッド filed Critical ソルスティス バイオロジクス，リミティッド
Publication of JP2017522046A publication Critical patent/JP2017522046A/ja
Publication of JP2017522046A5 publication Critical patent/JP2017522046A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017516650A 2014-06-06 2015-06-08 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 Pending JP2017522046A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009123P 2014-06-06 2014-06-06
US62/009,123 2014-06-06
PCT/US2015/034749 WO2015188197A2 (en) 2014-06-06 2015-06-08 Polynucleotide constructs having bioreversible and non-bioreversible groups

Publications (2)

Publication Number Publication Date
JP2017522046A true JP2017522046A (ja) 2017-08-10
JP2017522046A5 JP2017522046A5 (enExample) 2018-07-19

Family

ID=54767614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516650A Pending JP2017522046A (ja) 2014-06-06 2015-06-08 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物

Country Status (7)

Country Link
US (2) US20170114341A1 (enExample)
EP (1) EP3152308A4 (enExample)
JP (1) JP2017522046A (enExample)
CN (1) CN107109405A (enExample)
AU (1) AU2015269053A1 (enExample)
CA (1) CA2950960A1 (enExample)
WO (1) WO2015188197A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019039403A1 (ja) * 2017-08-22 2020-11-26 国立大学法人東海国立大学機構 修飾ポリヌクレオチド
JP2021509402A (ja) * 2017-12-29 2021-03-25 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドＳｕｚｈｏｕ Ｒｉｂｏ Ｌｉｆｅ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． 複合体及びその調製方法と使用
JP2022515503A (ja) * 2018-12-28 2022-02-18 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
JP2022546055A (ja) * 2019-08-29 2022-11-02 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 化合物、薬物複合体及びその調製方法と使用
WO2023113038A1 (ja) * 2021-12-17 2023-06-22 リードファーマ株式会社 オリゴヌクレオチドの製造方法

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
KR102713216B1 (ko) 2015-06-25 2024-10-02 로스웰 엠이 아이엔씨. 바이오분자 센서들 및 방법들
EP3386517A4 (en) * 2015-12-08 2019-08-07 Solstice Biologics, Ltd. POLYNUCLEOTIDE CONSTRUCTS COMPRISING AN AUXILIARY FRACTION RELATED NON-BIOREVERSIBLE TO AN INTERNETOSIDIC PHOSPHATE OR PHOSPHOROTHIOATE
JP7109785B2 (ja) 2016-01-14 2022-08-01 ロズウェル バイオテクノロジーズ，インコーポレイテッド 分子センサーおよび関連方法
US10712334B2 (en) 2016-01-28 2020-07-14 Roswell Biotechnologies, Inc. Massively parallel DNA sequencing apparatus
EP3408220A4 (en) 2016-01-28 2019-09-04 Roswell Biotechnologies, Inc METHOD AND DEVICE FOR MEASURING ANALYTES USING LARGE CALCULAR MOLECULAR ELECTRONIC SENSOR ARRAYS
US10737263B2 (en) 2016-02-09 2020-08-11 Roswell Biotechnologies, Inc. Electronic label-free DNA and genome sequencing
US10597767B2 (en) 2016-02-22 2020-03-24 Roswell Biotechnologies, Inc. Nanoparticle fabrication
EP3429618B1 (en) 2016-03-16 2024-02-21 Amal Therapeutics SA Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
US9829456B1 (en) 2016-07-26 2017-11-28 Roswell Biotechnologies, Inc. Method of making a multi-electrode structure usable in molecular sensing devices
JP7022443B2 (ja) * 2016-08-01 2022-02-18 ロズウェル バイオテクノロジーズ，インコーポレイテッド 分子電子センサーのための修飾ヌクレオチド三リン酸
WO2018035380A1 (en) * 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
MX2019002075A (es) * 2016-08-23 2019-07-01 Dicerna Pharmaceuticals Inc Composiciones que comprenden oligonucleotidos modificados reversiblemente, y sus usos.
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
CN110431148A (zh) 2017-01-10 2019-11-08 罗斯威尔生命技术公司 用于dna数据存储的方法和系统
US10450565B2 (en) 2017-01-10 2019-10-22 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
KR102685937B1 (ko) 2017-01-19 2024-07-17 로스웰 엠이 아이엔씨. 2차원 레이어 재료를 포함하는 솔리드 스테이트 시퀀싱 디바이스들
BR112019021520A2 (pt) * 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
KR102692957B1 (ko) 2017-04-25 2024-08-06 로스웰 엠이 아이엔씨. 분자 센서들을 위한 효소 회로들
CN110651182B (zh) 2017-05-09 2022-12-30 罗斯威尔生命技术公司 用于分子传感器的结合探针电路
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
EP3676389A4 (en) 2017-08-30 2021-06-02 Roswell Biotechnologies, Inc PROCESSIVE ENZYMATIC MOLECULAR ELECTRONIC SENSORS FOR STORING DNA DATA
WO2019075100A1 (en) 2017-10-10 2019-04-18 Roswell Biotechnologies, Inc. METHODS, APPARATUS AND SYSTEMS FOR STORING DNA DATA WITHOUT AMPLIFICATION
EP3684377B1 (en) 2017-10-20 2022-12-07 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis b infection
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7360716B2 (ja) 2017-12-01 2023-10-13 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105414A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HRP20250277T1 (hr) 2017-12-01 2025-05-09 Suzhou Ribo Life Science Co., Ltd. Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
EP3710588A4 (en) 2018-01-16 2021-08-18 Dicerna Pharmaceuticals, Inc. COMPOSITIONS AND METHODS TO INHIBIT ALDH2 EXPRESSION
AU2019222767A1 (en) 2018-02-14 2020-08-27 Deep Genomics Incorporated Oligonucleotide therapy for Wilson disease
CA3098623A1 (en) 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
BR112021000538A2 (pt) 2018-07-13 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modular a expressão de rtel1
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
JP7376952B2 (ja) 2018-09-30 2023-11-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド ｓｉＲＮＡ複合体及びその調製方法と使用
AU2019360216A1 (en) * 2018-10-17 2021-05-13 Tallac Therapeutics, Inc. Immunomodulating polynucleotide conjugates and methods of use
US11249941B2 (en) * 2018-12-21 2022-02-15 Palo Alto Research Center Incorporated Exabyte-scale data storage using sequence-controlled polymers
CN112423795B (zh) * 2018-12-28 2026-06-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2020167593A1 (en) 2019-02-12 2020-08-20 Dicerna Pharmaceuticals, Inc. Methods and compositions for inhibiting expression of cyp27a1
AU2020252560A1 (en) 2019-04-04 2021-10-28 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
CN113286888B (zh) 2019-05-22 2023-12-22 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
JP7610848B2 (ja) 2019-05-22 2025-01-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
CN113227376B (zh) 2019-05-22 2024-04-09 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN113795280B (zh) * 2019-05-24 2024-04-05 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
AU2020286462B2 (en) 2019-06-06 2026-07-02 Arrowhead Pharmaceuticals, Inc. Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)
CN112390835A (zh) * 2019-08-14 2021-02-23 苏州瑞博生物技术股份有限公司 肝靶向化合物及缀合物
US20220389430A1 (en) 2019-10-02 2022-12-08 Dicema Pharmaceuticals, Inc. Chemical modifications of small interfering rna with minimal fluorine content
CA3164050A1 (en) 2019-12-09 2021-06-17 Empirico Inc. Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases
EP4081639A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
EP4081217A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
CA3172117A1 (en) 2020-03-18 2021-09-23 Bob D. Brown Compositions and methods for inhibiting angptl3 expression
JP2023537499A (ja) 2020-08-04 2023-09-01 ディセルナ ファーマシューティカルズ インコーポレイテッド オリゴヌクレオチドの全身送達
TW202221120A (zh) 2020-08-04 2022-06-01 美商黛瑟納製藥公司 用於治療代謝症候群之組成物及方法
KR20250077604A (ko) 2020-08-05 2025-05-30 다이서나 파마수이티컬, 인크. Lpa 발현을 저해하기 위한 조성물 및 방법
JP2023536999A (ja) 2020-08-05 2023-08-30 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎患者のオリゴヌクレオチド処置
TW202228729A (zh) 2020-10-08 2022-08-01 美商戴瑟納製藥股份有限公司 選擇性遞送寡核苷酸至膠細胞
WO2022081867A1 (en) * 2020-10-14 2022-04-21 North Carolina State University Compositions and methods for drug delivery
CN115209922A (zh) * 2021-01-28 2022-10-18 南京桦冠生物技术有限公司 缀合物及其用途
IL305634A (en) 2021-03-05 2023-11-01 Dicerna Pharmaceuticals Inc Rnai conjugates and uses thereof
KR20230171431A (ko) 2021-04-14 2023-12-20 다이서나 파마수이티컬, 인크. Pnpla3 발현을 조절하기 위한 조성물 및 방법
AU2022384619A1 (en) 2021-11-11 2024-04-11 F. Hoffmann-La Roche Ag Pharmaceutical combinations for treatment of hbv
JP7877458B2 (ja) 2021-12-01 2026-06-22 ディセルナ ファーマシューティカルズ インコーポレイテッド Ａｐｏｃ３発現を調節するための組成物及び方法
IL315546A (en) 2022-03-16 2024-11-01 Empirico Inc GALNAC compositions to improve siRNA bioavailability
JP2025512445A (ja) 2022-04-15 2025-04-17 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｓｃａｐ活性を調節するための組成物及び方法
WO2024093947A1 (zh) * 2022-10-31 2024-05-10 大睿生物医药科技(上海)有限公司 向细胞内递送siRNA的前药
CN115925586A (zh) * 2022-11-01 2023-04-07 青岛蓝谷多肽生物医药科技有限公司 一种靶向psma的母体及其衍生物的制备方法
WO2024097310A2 (en) * 2022-11-01 2024-05-10 Impilo Therapeutics, Inc. Targeted non-charged-nucleic acid (ncna) delivery and related tumor penetrating nanocomplexes
TW202430637A (zh) 2022-11-16 2024-08-01 美商戴瑟納製藥股份有限公司 Stat3靶向性寡核苷酸及其用途
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
CN116925160B (zh) * 2023-09-15 2023-12-08 天津全和诚科技有限责任公司 一种GalNAc含糖环中间体及其制备方法
WO2025235911A2 (en) * 2024-05-09 2025-11-13 Wave Life Sciences Ltd. Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto
WO2026117631A2 (en) 2024-11-26 2026-06-04 City Therapeutics, Inc. Factor xi rnai agent compositions and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040459A1 (en) * 2008-09-22 2012-02-16 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
US20120142763A1 (en) * 2009-06-01 2012-06-07 The Regents Of The University Of California Nucleic acid delivery compositions and methods of use thereof
WO2014031575A1 (en) * 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2651453C (en) * 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
CN106061981A (zh) * 2013-11-06 2016-10-26 索尔斯蒂斯生物有限公司 具有二硫化物基团的多核苷酸构建体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040459A1 (en) * 2008-09-22 2012-02-16 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
US20120142763A1 (en) * 2009-06-01 2012-06-07 The Regents Of The University Of California Nucleic acid delivery compositions and methods of use thereof
WO2014031575A1 (en) * 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CURR. PROTOC. NUCLEIC ACID CHEM., 2008, VOL.35, 4.33.1-4.33.21, JPN6019028553, ISSN: 0004082367 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019039403A1 (ja) * 2017-08-22 2020-11-26 国立大学法人東海国立大学機構 修飾ポリヌクレオチド
JP7282379B2 (ja) 2017-08-22 2023-05-29 国立大学法人東海国立大学機構 修飾ポリヌクレオチド
JP2021509402A (ja) * 2017-12-29 2021-03-25 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドＳｕｚｈｏｕ Ｒｉｂｏ Ｌｉｆｅ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． 複合体及びその調製方法と使用
JP7436030B2 (ja) 2017-12-29 2024-02-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 複合体及びその調製方法と使用
JP2022515503A (ja) * 2018-12-28 2022-02-18 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
JP2022546055A (ja) * 2019-08-29 2022-11-02 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 化合物、薬物複合体及びその調製方法と使用
WO2023113038A1 (ja) * 2021-12-17 2023-06-22 リードファーマ株式会社 オリゴヌクレオチドの製造方法

Also Published As

Publication number Publication date
US20170114341A1 (en) 2017-04-27
AU2015269053A1 (en) 2016-12-22
CN107109405A (zh) 2017-08-29
US20200392498A1 (en) 2020-12-17
CA2950960A1 (en) 2015-12-10
WO2015188197A3 (en) 2016-02-25
EP3152308A4 (en) 2017-12-27
EP3152308A2 (en) 2017-04-12
WO2015188197A2 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
US20200392498A1 (en) Polynucleotide constructs having bioreversible and non-bioreversible groups
US20160257961A1 (en) Polynucleotide constructs having disulfide groups
US20240247025A1 (en) Polynucleotide constructs
AU2013306006B2 (en) Polynucleotides having bioreversible groups
US20240175019A1 (en) Skeletal Muscle Delivery Platforms and Methods of Use
US20190194655A1 (en) Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
CN101506368A (zh) 通过可逆的磷酸三酯电荷中和保护基转导运输核酸
CN115427051B (zh) 治疗剂及其结合物
WO2012074038A1 (ja) 修飾１本鎖ポリヌクレオチド
WO2023045995A1 (en) Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents
KR20260056195A (ko) 올리고뉴클레오타이드의 세포내 표적화

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200331